Targeting Zfp36 to combat cardiac hypertrophy: Insights into ferroptosis pathways

Abstract

	•Zfp36 was initially demonstrated to attenuate cardiac hypertrophy through the inhibition of ferroptosis in cardiomyocytes, providing a new target for therapeutic strategies targeting ferroptosis.
	•Zfp36 facilitated the degradation of Ythdc2 mRNA by binding to it, subsequently inhibiting Ythdc2-mediated degradation of SLC7A11 mRNA, and maintaining GSH levels. This elucidates a previously unrecognized regulatory pathway in the context of cardiac hypertrophy.

Keywords

cardiac hypertrophy / ferroptosis / RNA binding / Ythdc2 / Zfp36

References

[1] Li C, Li S, Zhang G, et al. Ire1α mediates the hypertrophic growth of cardiomyocytes through facilitating the formation of initiation complex to promote the translation of top-motif transcripts. Circulation. 2024;150(13):1010-1029.

[2] Martin TG, Juarros MA, Leinwand LA. Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nat Rev Cardiol. 2023;20(5):347-363.

[3] Nakamura M, Sadoshima J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat Rev Cardiol. 2018;15(7):387-407.

[4] Liu D, Qin H, Gao Y, Sun M, Wang M. Cardiovascular disease: mitochondrial dynamics and mitophagy crosstalk mechanisms with novel programmed cell death and macrophage polarisation. Pharmacol Res. 2024;206:107258.

[5] Li L, Gao P, Tang X, et al. Cb1r-stabilized Nlrp3 inflammasome drives antipsychotics cardiotoxicity. Signal Transduct Target Ther. 2022;7(1):190.

[6] Gao P, Cao M, Jiang X, et al. Cannabinoid receptor 2-centric molecular feedback loop drives necroptosis in diabetic heart injuries. Circulation. 2023;147(2):158-174.

[7] Yu H, Gan D, Luo Z, et al. α-Ketoglutarate improves cardiac insufficiency through NAD+-SIRT1 signaling-mediated mitophagy and ferroptosis in pressure overload-induced mice. Mol Med. 2024;30(1):15.

[8] Dixon SJ, Olzmann JA. The cell biology of ferroptosis. Nat Rev Mol Cell Biol. 2024;25(6):424-442.

[9] Fang X, Ardehali H, Min J, Wang F. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat Rev Cardiol. 2023;20(1):7-23.

[10] Bi X, Wu X, Chen J, et al. Characterization of ferroptosis-triggered pyroptotic signaling in heart failure. Signal Transduct Target Ther. 2024;9(1):257.

[11] Li T, Sun M, Sun Q, et al. Pm(2.5)-induced iron homeostasis imbalance triggers cardiac hypertrophy through ferroptosis in a selective autophagy crosstalk manner. Redox Biol. 2024;72:103158.

[12] Zhang K, Tian XM, Li W, Hao LY. Ferroptosis in cardiac hypertrophy and heart failure. Biomed Pharmacother. 2023;168:115765.

[13] Diaz-Muñoz MD, Osma-Garcia IC. The RNA regulatory programs that govern lymphocyte development and function. Wiley Interdiscip Rev RNA. 2022;13(1):e1683.

[14] Snyder BL, Blackshear PJ. Clinical implications of tristetraprolin (Ttp) modulation in the treatment of inflammatory diseases. Pharmacol Ther. 2022;239:108198.

[15] Yadav S, El Hamra R, Alturki NA, et al. Regulation of Zfp36 by Isgf3 and Mk2 restricts the expression of inflammatory cytokines during necroptosis stimulation. Cell Death Dis. 2024;15(8):574.

[16] Li X, Hu Y, Wu Y, Yang Z, Liu Y, Liu H. Exosomal Let-7a-5p derived from human umbilical cord mesenchymal stem cells alleviates coxsackievirus B3-induced cardiomyocyte ferroptosis via the Smad2/Zfp36 signal axis. J Zhejiang Univ Sci B. 2024;25(5):422-437.

[17] Zhang M, Zhang X, Niu J, Hua C, Liu P, Zhong G. Integrated analysis of single-cell RNA sequencing and bulk RNA data reveals gene regulatory networks and targets in dilated cardiomyopathy. Sci Rep. 2024;14(1):13942.

[18] Cui X, Wang Y, Lu H, et al. Zfp36 regulates vascular smooth muscle contraction and maintains blood pressure. Adv Sci. 2025;12(3):e2408811.

[19] Liu J, Cao X. RBP-RNA interactions in the control of autoimmunity and autoinflammation. Cell Res. 2023;33(2):97-115.

[20] Wang M, Li Y, Xiao Y, et al. Nicotine-mediated Otud3 downregulation inhibits Vegf-C Mrna decay to promote lymphatic metastasis of human esophageal cancer. Nat Commun. 2021;12(1):7006.

[21] Ma L, Chen T, Zhang X, et al. The M(6)a reader Ythdc2 inhibits lung adenocarcinoma tumorigenesis by suppressing Slc7a11-dependent antioxidant function. Redox Biol. 2021;38:101801.

[22] Koppula P, Zhang Y, Zhuang L, Gan B. Amino acid transporter Slc7a11/Xct at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun. 2018;38(1):12.

[23] Chen K, Wang S, Sun QW, Zhang B, Ullah M, Sun Z. Klotho deficiency causes heart aging via impairing the Nrf2-Gr pathway. Circ Res. 2021;128(4):492-507.

[24] Peng F, Liao M, Jin W, et al. 2-Apqc, a small-molecule activator of sirtuin-3 (Sirt3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis. Signal Transduct Target Ther. 2024;9(1):133.

[25] Maremonti F, Tonnus W, Gavali S, et al. Ferroptosis-based advanced therapies as treatment approaches for metabolic and cardiovascular diseases. Cell Death Differ. 2024;31(9):1104-1112.

[26] Zhang W, Lu J, Wang Y, et al. Canagliflozin attenuates lipotoxicity in cardiomyocytes by inhibiting inflammation and ferroptosis through activating Ampk pathway. Int J Mol Sci. 2023;24(1):858.

[27] Yuan J, Yin C, Peng H, et al. Ndrg1 regulates iron metabolism and inhibits pathologic cardiac hypertrophy. Can J Cardiol. 2024;41(2):224-240.

[28] Yoshida M, Minagawa S, Araya J, et al. Involvement of cigarette smoke-induced epithelial cell ferroptosis in COPD pathogenesis. Nat Commun. 2019;10(1):3145.

[29] Xu W, Billon C, Li H, et al. Novel Pan-Err agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation. 2024;149(3):227-250.

[30] Alsereidi FR, Khashim Z, Marzook H, et al. Dapagliflozin mitigates cellular stress and inflammation through Pi3k/Akt pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived Β cells. Cardiovasc Diabetol. 2024;23(1):388.

[31] Qi Y, Xu H, Li X, et al. Silica nanoparticles induce cardiac injury and dysfunction via Ros/Ca(2+)/Camkii signaling. Sci Total Environ. 2022;837:155733.

[32] Qiu H, Sun Y, Wang X, et al. Lamin A/C deficiency-mediated Ros elevation contributes to pathogenic phenotypes of dilated cardiomyopathy in IPSC model. Nat Commun. 2024;15(1):7000.

[33] Newton K, Strasser A, Kayagaki N, Dixit VM. Cell death. Cell. 2024;187(2):235-256.

[34] Shen M, Cao S, Long X, et al. Dnajc12 causes breast cancer chemotherapy resistance by repressing doxorubicin-induced ferroptosis and apoptosis via activation of Akt. Redox Biol. 2024;70:103035.

[35] Yuan J, Ofengeim D. A guide to cell death pathways. Nat Rev Mol Cell Biol. 2024;25(5):379-395.

[36] Baumgarten G, Knuefermann P, Kalra D, et al. Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation. 2002;105(18):2192-2197.

[37] Zhao J, Yang S, Lv C, Liu Y. Cancer-associated fibroblasts suppressed ferroptosis in glioblastoma via upregulating Lncrna Dleu1. Am J Physiol Cell Physiol. 2023;324(5):C1039-C1052.

[38] Cicchetto AC, Jacobson EC, Sunshine H, et al. Zfp36-mediated Mrna decay regulates metabolism. Cell Rep. 2023;42(5):112411.

[39] Wang W, Zhang TN, Yang N, et al. Transcriptome-wide identification of altered RNA M(6)a profiles in cardiac tissue of rats with LPS-induced myocardial injury. Front Immunol. 2023;14:1122317.

[40] Zhang X, Zheng C, Gao Z, et al. Slc7a11/Xct prevents cardiac hypertrophy by inhibiting ferroptosis. Cardiovasc Drugs Ther. 2022;36(3):437-447.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.